Description
CD73 (Immuno-Oncology Target)(NT5E/2646), CF568 conjugate, 0.1mg/mL Antibody | BNC682646-100| Gentaur Distribution US, UK & Europe
Summary.: CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma, colorectal, gastric, triple negative breast cancer, and to a pro-metastatic phenotype in prostate cancer. Together with CD39, it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment, ATP promotes immune cell-mediated killing of cancer cells. In contrast, adenosine accumulation causes immune suppression, dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway, where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly, anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in Mouse tumor models, and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors. .
Conjugate: CF568.
Storage Buffer: PBS, 0.1% BSA, 0.05% azide.
Storage Temperature: 2°C to 8°C.
Application: Flow (verified)|IF (verified)|IHC, FFPE (verified)|WB (verified).
Stability: Stable at room temperature or 37°C (98°F) for 7 days.
